IKT

Over the past six months, Inhibikase Therapeutics' stock has been influenced by several key events including the announcement of quarterly and full-year financial results, the granting of FDA Orphan Drug Designation for IKT-001 for PAH, the sale of shares through an ATM facility, inducement grants, and significant progress in the IMPROVE-PAH global Phase 3 study with the enrollment of the first patient. These events, along with positive FDA designations and promising results, led to notable stock price increases, although the company also paused its Parkinson's program.